Qual Life Res (2017) 26:2479–2488 DOI 10.1007/s11136-017-1574-9 The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries 1,2 2 3 2,4 • • • • Sarah Kleijnen Teresa Leonardo Alves Kim Meijboom Iga Lipska 2 2 1,2 • • Anthonius De Boer Hubertus G. Leufkens Wim G. Goettsch Accepted: 4 April 2017 / Published online: 11 April 2017 The Author(s) 2017. This article is an open access publication Abstract assessments. Developing and implementing into REAs Purpose The aim of this study is to investigate the role of speciﬁc evidence requirements for QoL data would health-related quality-of-life (QoL) data in relative effec- improve the use of this patient-centred outcome in future tiveness assessments (REAs) of new anti-cancer drugs reimbursement and pricing decisions. across European jurisdictions, during health technology assessment procedures. Keywords Comparative effectiveness Quality of life Methods Comparative analysis of guidelines and publicly Health technology assessment Reimbursement available REAs in six European jurisdictions of anti-cancer Antineoplastic agents Patient-centred outcome research drugs approved by EMA between 2011 and 2013. Results Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a Introduction relevant endpoint to
Quality of Life Research – Springer Journals
Published: Apr 11, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud